What is Zacks Research’s Estimate for Omnicell Q1 Earnings?

Omnicell, Inc. (NASDAQ:OMCL) – Investment analysts at Zacks Research issued their Q1 2025 earnings per share estimates for shares of Omnicell in a research note issued to investors on Tuesday, February 25th. Zacks Research analyst R. Department anticipates that the company will earn ($0.03) per share for the quarter. The consensus estimate for Omnicell’s current full-year earnings is $1.09 per share. Zacks Research also issued estimates for Omnicell’s Q3 2025 earnings at $0.31 EPS, Q4 2025 earnings at $0.44 EPS, FY2025 earnings at $0.95 EPS, Q1 2026 earnings at $0.19 EPS, Q2 2026 earnings at $0.29 EPS, Q3 2026 earnings at $0.29 EPS, Q4 2026 earnings at $0.38 EPS and FY2026 earnings at $1.16 EPS.

A number of other equities analysts have also recently issued reports on the stock. Benchmark reissued a “buy” rating and issued a $62.00 target price on shares of Omnicell in a report on Tuesday, February 4th. StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a report on Tuesday, December 10th. JPMorgan Chase & Co. raised their target price on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Wells Fargo & Company cut their target price on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Finally, Bank of America cut their target price on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a report on Monday, January 6th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, Omnicell presently has a consensus rating of “Hold” and a consensus price target of $52.33.

Omnicell Stock Performance

Shares of OMCL stock opened at $38.06 on Thursday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. Omnicell has a one year low of $25.12 and a one year high of $55.74. The company’s 50-day simple moving average is $42.39 and its 200-day simple moving average is $43.80. The stock has a market capitalization of $1.76 billion, a price-to-earnings ratio of 140.97, a PEG ratio of 7.53 and a beta of 0.78.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%.

Insider Buying and Selling at Omnicell

In related news, Director Mark W. Parrish sold 12,000 shares of Omnicell stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total value of $567,600.00. Following the completion of the sale, the director now owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. The trade was a 17.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 2.64% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of OMCL. Victory Capital Management Inc. raised its holdings in Omnicell by 11,982.3% in the 3rd quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock worth $50,071,000 after acquiring an additional 1,138,921 shares during the period. Sumitomo Mitsui Trust Group Inc. bought a new position in shares of Omnicell during the 3rd quarter worth about $32,721,000. Lazard Asset Management LLC increased its holdings in shares of Omnicell by 81.6% during the 4th quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company’s stock worth $73,093,000 after purchasing an additional 737,536 shares during the period. Toronto Dominion Bank bought a new position in shares of Omnicell during the 4th quarter worth about $30,637,000. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Omnicell by 31.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company’s stock worth $73,127,000 after purchasing an additional 394,820 shares during the period. Institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.